462 related articles for article (PubMed ID: 33901324)
81. Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study.
Mondesir J; Alary AS; Sibon D; Willems L; Deau B; Suarez F; Hermine O; Fontenay M; Bouscary D; Kosmider O; Tamburini J
Br J Haematol; 2019 Oct; 187(1):65-72. PubMed ID: 31215036
[TBL] [Abstract][Full Text] [Related]
82. [Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].
Duan MH; Zhang Y; Zhang M; Han X; Zhang Y; Yang C; Feng J; Zhang L; Zhang W; Li J; Tian LP; Zhang Y; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):571-5. PubMed ID: 27535856
[TBL] [Abstract][Full Text] [Related]
83. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.
Dillon R; Maycock S; Jackson A; Fox S; Freeman S; Craddock C; Thomas C; Homer E; Leahy J; Mamwell A; Potter N; Russell N; Wei A; Ommen HB; Hemmaway C; Knapper S; Billingham L
BMC Cancer; 2022 Nov; 22(1):1174. PubMed ID: 36376888
[TBL] [Abstract][Full Text] [Related]
84. [Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
Wu M; Ma IX; Xie YH; Ye XJ; He HS; Hua JS; Yang RY; Wang XH; Wang XQ; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1991-1997. PubMed ID: 33283731
[TBL] [Abstract][Full Text] [Related]
85. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
86. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract][Full Text] [Related]
87. Efficacy and safety of cladribine addition to induction treatment of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.
Pan Q; Li J
Hematology; 2021 Dec; 26(1):577-587. PubMed ID: 34384339
[TBL] [Abstract][Full Text] [Related]
88. Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
Gangat N; Tefferi A
Blood Cancer J; 2020 Nov; 10(11):122. PubMed ID: 33230098
[TBL] [Abstract][Full Text] [Related]
89. [Effectiveness of CLAT Protocol for Treating Patients with Refractory Acute Myeloid Leukemia].
Chen XM; Weng JY; Deng CX; Wang YL; Chao Z; Lai PL; Li MM; Liao PJ; Huang X; Ling W; Wan CC; Wu SJ; Zhong LY; Lu ZS; Zou XL; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):399-404. PubMed ID: 27150999
[TBL] [Abstract][Full Text] [Related]
90. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS).
Kantarjian HM; Begna KH; Altman JK; Goldberg SL; Sekeres MA; Strickland SA; Arellano ML; Claxton DF; Baer MR; Gautier M; Berman E; Seiter K; Solomon SR; Schiller GJ; Luger SM; Butrym A; Gaidano G; Thomas XG; Montesinos P; Rizzieri DA; Quick DP; Venugopal P; Gaur R; Maness LJ; Kadia TM; Ravandi F; Buyse ME; Chiao JH
Cancer; 2021 Dec; 127(23):4421-4431. PubMed ID: 34424530
[TBL] [Abstract][Full Text] [Related]
91. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
Löwenberg B; Pabst T; Maertens J; van Norden Y; Biemond BJ; Schouten HC; Spertini O; Vellenga E; Graux C; Havelange V; de Greef GE; de Weerdt O; Legdeur MJ; Kuball J; Kooy MV; Gjertsen BT; Jongen-Lavrencic M; van de Loosdrecht AA; van Lammeren-Venema D; Hodossy B; Breems DA; Chalandon Y; Passweg J; Valk PJ; Manz MG; Ossenkoppele GJ;
Blood; 2017 Mar; 129(12):1636-1645. PubMed ID: 28049642
[TBL] [Abstract][Full Text] [Related]
92. Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).
Krauter J; Fiedler W; Schlenk RF; Paschka P; Thol F; Lübbert M; Wattad M; Verbeek M; Könecke C; Neuhaus B; Papkalla A; Kebenko M; Janning M; Döhner K; Gaidzik VI; Becker H; Greil C; Reimer P; Götze KS; Döhner H; Ganser A; Heuser M
Br J Haematol; 2018 Oct; 183(2):235-241. PubMed ID: 30378121
[TBL] [Abstract][Full Text] [Related]
93. Dose-Reduced Decitabine Might Bring Benefits for Elderly AML Patients with Complex Karyotype: a Case Report.
Sun Y; Wu C; Liu C; Shao Z
Clin Lab; 2020 Jul; 66(7):. PubMed ID: 32658429
[TBL] [Abstract][Full Text] [Related]
94. Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia.
Griffiths EA; Carraway HE; Chandhok NS; Prebet T
Leuk Res; 2020 Apr; 91():106339. PubMed ID: 32146154
[TBL] [Abstract][Full Text] [Related]
95. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
Price SL; Lancet JE; George TJ; Wetzstein GA; List AF; Ho VQ; Fernandez HF; Pinilla-Ibarz J; Kharfan-Dabaja MA; Komrokji RS
Leuk Res; 2011 Mar; 35(3):301-4. PubMed ID: 21109304
[TBL] [Abstract][Full Text] [Related]
96. Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Fong CY; Grigoriadis G; Hocking J; Coutsouvelis J; Muirhead J; Campbell P; Paul E; Walker P; Avery S; Patil S; Spencer A; Schwarer A; Wei A
Leuk Lymphoma; 2013 Feb; 54(2):336-41. PubMed ID: 22812445
[TBL] [Abstract][Full Text] [Related]
97. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
[TBL] [Abstract][Full Text] [Related]
98. Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia.
Cascino GJ; Voss WB; Canaani J; Furiasse N; Rademaker A; Ky B; Luger S; Altman JK; Foran JM; Litzow MR; Tallman MS; Rigolin V; Akhter N
Echocardiography; 2019 Nov; 36(11):2033-2040. PubMed ID: 31705570
[TBL] [Abstract][Full Text] [Related]
99. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Holowiecki J; Grosicki S; Giebel S; Robak T; Kyrcz-Krzemien S; Kuliczkowski K; Skotnicki AB; Hellmann A; Sulek K; Dmoszynska A; Kloczko J; Jedrzejczak WW; Zdziarska B; Warzocha K; Zawilska K; Komarnicki M; Kielbinski M; Piatkowska-Jakubas B; Wierzbowska A; Wach M; Haus O
J Clin Oncol; 2012 Jul; 30(20):2441-8. PubMed ID: 22508825
[TBL] [Abstract][Full Text] [Related]
100. Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis.
Zhou A; Han Q; Song H; Zi J; Ma J; Ge Z
Drug Des Devel Ther; 2019; 13():1867-1878. PubMed ID: 31213774
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
